Less bleeding by omitting aspirin in non-ST-segment elevation acute coronary syndrome patients: Rationale and design of the LEGACY study
Study context
- Population
- Patients after successful percutaneous coronary intervention (PCI) for NSTE-ACSplanned
- Participants
- 3,090 patients
- Planned comparison
- Immediate P2Y12-inhibitor monotherapy vs dual antiplatelet therapy (DAPT) for 12 months
- Primary endpoint
- Major or minor bleeding (BARC type 2, 3 or 5); noninferiority for composite of all-cause mortality, MI and stroke
- Follow-up
- 12 months
Methodological detailsrationale and design, open-label, multicentre
- Rationale and design
- Open-label
- Multicentre
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Less bleeding by omitting aspirin in non-ST-segment elevation acute coronary syndrome patients: Rationale and design of the LEGACY study. Am Heart J. Published 28 July 2023. doi:10.
Summarised from the published abstract; every number is checked against it